Stroke Patients Needed for IRIS Trials

UW Health Services
MADISON - Even after people recover from an initial stroke or transient ischemic attack, statistics give reason to worry. Within five years, as many as a quarter of all ischemic stroke patients will suffer a second stroke and about half that many will suffer a heart attack. Researchers at UW School of Medicine and Public Health are part of a large national study that seeks to find out whether treating non-diabetic stroke patients for insulin resistance can help improve these odds.

It has been estimated that insulin resistance affects about half of all stroke patients. The condition means their bodies make insulin but it doesn’t turn the sugar in the blood into energy as it should, leading to high blood glucose levels. Insulin resistance may lead to diabetes and blood vessel disease that can cause stroke and heart attack.

Neurologist Justin Sattin, MD, of the UW Health Stroke Program, hopes to enroll 26 stroke patients who have insulin resistance, but who are not yet diabetic. They will participate in a study in which some of the patients will receive ploglitazone, a drug that treats insulin resistance, and that is currently prescribed to some diabetics. Other patients will receive a placebo. The study is double blind, meaning neither the researchers nor the participants will know which drug they are getting.

The study will involve at least four, 30-minute clinic visits and 12 phone contacts.

The UW research is part of the large Insulin Resistance Intervention after Stroke (IRIS) study, being founded by the National Institute of Neurological Disorders and Stroke at 100 hospitals nationwide. In all, about 3,100 stroke patients will take part in the trial.

If you have patients that may be interested in participating in this trial, please contact XXXX.